NUCLEAR PLANT TYCOON GROUP CODES SKIN
Under the Agreement, Tycoon will arrange and ensure the sale channels of pharmaceutical and health products and coordinate cooperation with third parties in Hong Kong and Macau, supply comprehensive and premium brands of PCM which are representative in Hong Kong and Macau and strive to cover the Blue Ocean Market of PCM in Greater Bay Area (GBA) Guobiao will provide one-step service for quality standard research and registration and testing and coordinate cooperation with third parties in China and provide consultation services for entry of the pharmaceutical and health product market in Guangdong- Hong Kong- Macau and the GBA CR Guangdong will leverage its advantage as pharmaceutical import platform for the GBA to extend its international supply chain services, exploring innovative supply chain service models with pharmaceutical enterprises and medical diagnostic devise companies and coordinate cooperation with third parties in Guangdong, China.Īs a leading provider of a number of PCM, health supplement, skin care, personal care and other healthcare products, predominately in Hong Kong, Tycoon Group believes that the Framework Agreement can fully utilise the resources and advantages of the three parties in their respective fields, promote comprehensive cooperation between the parties and bring significant business opportunities to the Group's business in Guangdong- Hong Kong- Macau and the GBA.
NUCLEAR PLANT TYCOON GROUP CODES FULL
22, 2021 /PRNewswire/ - Tycoon Group Holdings Limited (" Tycoon" or the " Company" and its subsidiaries (together, the "Group"), Stock Code: 3390), an omnichannel brand marketing and management service integrator of health and well-being related products in Hong Kong, is pleased to announce that on 22 November 2021, Tycoon Asia Pacific Group Limited, an indirectly wholly-owned subsidiary of the Company, has entered into a strategic cooperation framework agreement (" Framework Agreement") with China Resources Guangdong Pharmaceutical Co., Ltd (" CR Guangdong"), a non-wholly-owned subsidiary of China Resources Pharmaceutical Group Limited (" China Resources Pharmaceutical", Stock Code: 3320), and Hong Kong Guobiao Inspection and Testing Co., Ltd (" Guobiao"), The three parties reached a preliminary understanding in relation to the further extensive cooperation in various areas including provision of integrated services for research and development and full commercial scale production of medicines in Guangdong- Hong Kong- Macau and the Greater Bay Area (" Business Cooperation").Ĭooperation of an Iron Triangle Helped Tycoon to Explore the Blue Ocean Market of Proprietary Chinese Medicine (PCM)Īccording to the Framework Agreement, the three parties agreed to achieve resources sharing, complement each other's advantages and hold regular meetings to facilitate cooperation and execution of the Agreements.
![nuclear plant tycoon group codes nuclear plant tycoon group codes](https://i.ytimg.com/vi/MFX0kuKapJQ/hqdefault.jpg)
Strived to Tap into the Blue Ocean Market of Proprietary Chinese Medicine in Greater Bay Area